Literature DB >> 18667868

Understanding and using the hospital standardized mortality ratio in Canada: challenges and opportunities.

Eugene Wen1, Carolyn Sandoval, Jennifer Zelmer, Greg Webster.   

Abstract

In 2005, the Canadian Institute for Health Information (CIHI) began a methodological journey to develop a Canadian version of the hospital standardized mortality ratio (HSMR). For two years, CIHI worked with hospitals, regional authorities and measurement experts to define the most appropriate methodology given Canadian datasets and systems of care. In November 2007, we made the findings publicly available for regional health authorities and larger facilities. In their lead article, Penfold et al. discuss their views regarding some methodological issues and potential limitations of the HSMR to monitor quality of care and, in particular, as a patient safety indicator. Here we respond to their specific concerns and maintain that the HSMR remains an important tool in the arsenal of information hospitals can use to focus the discussion of patient safety/quality improvement, monitor the provision of care over time and identify opportunities for improvement.

Entities:  

Mesh:

Year:  2008        PMID: 18667868     DOI: 10.12927/hcpap.2008.19973

Source DB:  PubMed          Journal:  Healthc Pap        ISSN: 1488-917X


  3 in total

1.  Patient safety and quality of care continue to improve in NHS North West following early implementation of the European Working Time Directive.

Authors:  J Collum; J Harrop; M Stokes; D Kendall
Journal:  QJM       Date:  2010-08-25

2.  The US hospital standardised mortality ratio: Retrospective database study of Massachusetts hospitals.

Authors:  Roxana Alexandrescu; Alex Bottle; Min Hua Jen; Brian Jarman; Paul Aylin
Journal:  JRSM Open       Date:  2015-01-19

3.  Hospital standardized mortality ratio: consequences of adjusting hospital mortality with indirect standardization.

Authors:  Maurice E Pouw; Linda M Peelen; Hester F Lingsma; Daniel Pieter; Ewout Steyerberg; Cor J Kalkman; Karel G M Moons
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.